UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


⌧ x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2022~~

2023


◻ o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES


An Illinois Corporation		I.R.S. Employer Identification No.
	36-0698440	~~36-0698440~~

100 Abbott Park Road

Abbott Park,, Illinois60064-6400

Telephone: (~~224~~) (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:



Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧x No ☐o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒x No ☐o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐o No ☒x

As of March 31, ~~2022,~~2023, Abbott Laboratories had ~~1,750,942,289~~1,738,946,799 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

Abbott Laboratories and Subsidiaries

~~Condensed~~

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

Three Months Ended

March 31

2022

2021
Net sales

$
11,895

$
10,456

Cost of products sold, excluding amortization of intangible assets

4,987

4,401
Amortization of intangible assets

512

509
Research and development

697

654
Selling, general and administrative

2,787

2,783
Total operating cost and expenses

8,983

8,347

Operating earnings

2,912

2,109

Interest expense

131

135
Interest (income)

(14)

(11)
Net foreign exchange (gain) loss

(3)

3
Other (income) expense, net

(78)

(61)
Earnings before taxes

2,876

2,043
Taxes on earnings

429

250
Net Earnings

$
2,447

$
1,793

Basic Earnings Per Common Share

$
1.38

$
1.00

Diluted Earnings Per Common Share

$
1.37

$
1.00

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share

1,761,911

1,776,842
Dilutive Common Stock Options

12,631

14,661
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options

1,774,542

1,791,503

Outstanding Common Stock Options Having No Dilutive Effect

2,655

2,694


	Three Months Ended
	March 31
	2023		2022
Net sales	$	9,747	$	11,895

Cost of products sold, excluding amortization of intangible assets	4,331		4,987
Amortization of intangible assets	491		512
Research and development	654		697
Selling, general and administrative	2,762		2,787
Total operating cost and expenses	8,238		8,983

Operating earnings	1,509		2,912

Interest expense	153		131
Interest (income)	(101)		(14)
Net foreign exchange (gain) loss	6		(3)
Other (income) expense, net	(111)		(78)
Earnings before taxes	1,562		2,876
Taxes on earnings	244		429
Net Earnings	$	1,318	$	2,447

Basic Earnings Per Common Share	$	0.75	$	1.38

Diluted Earnings Per Common Share	$	0.75	$	1.37

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,741,738		1,761,911
Dilutive Common Stock Options	9,977		12,631
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,751,715		1,774,542

Outstanding Common Stock Options Having No Dilutive Effect	7,332		2,655

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

~~(Unaudited)~~

(Unaudited)

(dollars in ~~millions)~~

millions)

Three Months Ended

March 31

2022

2021
Net Earnings

$
2,447

$
1,793

Foreign currency translation gain (loss) adjustments

(106)

(536)
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (costs) and credits, net of taxes of $13 in 2022 and $18 in 2021

62

85
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $(15) in 2022 and $46 in 2021

(56)

112
Other comprehensive income (loss)

(100)

(339)
Comprehensive Income (Loss)

$
2,347

$
1,454

March 31,

December 31,

2022

2021
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:

Cumulative foreign currency translation (loss) adjustments

$
(5,945)

$
(5,839)
Net actuarial (losses) and prior service (costs) and credits

(2,608)

(2,670)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges

79

135
Accumulated Other Comprehensive Income (Loss)

$
(8,474)

$
(8,374)


	Three Months Ended
	March 31
	2023		2022
Net Earnings	$	1,318	$	2,447
Foreign currency translation gain (loss) adjustments	139		(106)
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $— in 2023 and $13 in 2022	2		62
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(58) in 2023 and $(15) in 2022	(129)		(56)
Other comprehensive income (loss)	12		(100)
Comprehensive Income	$	1,330	$	2,347


	March 31, 2023		December 31, 2022
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(6,594)	$	(6,733)
Net actuarial (losses) and prior service (costs) and credits	(1,491)		(1,493)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges	46		175
Accumulated Other Comprehensive Income (Loss)	$	(8,039)	$	(8,051)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)

March 31,

December 31,

2022

2021
Assets

Current Assets:

Cash and cash equivalents

$
7,675

$
9,799
Short-term investments

483

450
Trade receivables, less allowances of $640 in 2022 and $519 in 2021

7,179

6,487
Inventories:

Finished products

3,470

3,081
Work in process

695

694
Materials

1,526

1,382
Total inventories

5,691

5,157
Prepaid expenses and other receivables

2,401

2,346
Total Current Assets

23,429

24,239
Investments

763

816
Property and equipment, at cost

19,521

19,364
Less: accumulated depreciation and amortization

10,613

10,405
Net property and equipment

8,908

8,959
Intangible assets, net of amortization

12,225

12,739
Goodwill

23,179

23,231
Deferred income taxes and other assets

5,503

5,212

$
74,007

$
75,196

Liabilities and Shareholders’ Investment

Current Liabilities:

Trade accounts payable

$
4,757

$
4,408
Salaries, wages and commissions

1,147

1,625
Other accrued liabilities

5,577

5,181
Dividends payable

824

831
Income taxes payable

338

306
Current portion of long-term debt

4

754
Total Current Liabilities

12,647

13,105
Long-term debt

17,086

17,296
Post-employment obligations, deferred income taxes and other long-term liabilities

8,645

8,771
Commitments and Contingencies

Shareholders’ Investment:

Preferred shares, 1 dollar par value Authorized — 1,000,000 shares, NaN issued

—

—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2022: 1,985,525,053; 2021: 1,985,273,421

24,304

24,470
Common shares held in treasury, at cost — Shares: 2022: 234,582,764; 2021: 221,191,228

(13,726)

(11,822)
Earnings employed in the business

33,295

31,528
Accumulated other comprehensive income (loss)

(8,474)

(8,374)
Total Abbott Shareholders’ Investment

35,399

35,802
Noncontrolling Interests in Subsidiaries

230

222
Total Shareholders’ Investment

35,629

36,024

$
74,007

$
75,196


	March 31, 2023		December 31, 2022
Assets
Current Assets:
Cash and cash equivalents	$	9,161	$	9,882
Short-term investments	371		288
Trade receivables, less allowances of $503 in 2023 and $500 in 2022	6,020		6,218
Inventories:
Finished products	3,944		3,805
Work in process	805		680
Materials	1,924		1,688
Total inventories	6,673		6,173
Prepaid expenses and other receivables	2,152		2,663
Total Current Assets	24,377		25,224
Investments	776		766
Property and equipment, at cost	20,605		20,212
Less: accumulated depreciation and amortization	11,323		11,050
Net property and equipment	9,282		9,162
Intangible assets, net of amortization	10,006		10,454
Goodwill	22,927		22,799
Deferred income taxes and other assets	6,426		6,033
	$	73,794	$	74,438
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable	$	4,167	$	4,607
Salaries, wages and commissions	1,098		1,556
Other accrued liabilities	5,758		5,845
Dividends payable	888		887
Income taxes payable	334		343
Current portion of long-term debt	2,285		2,251
Total Current Liabilities	14,530		15,489
Long-term debt	14,615		14,522
Post-employment obligations, deferred income taxes and other long-term liabilities	7,417		7,522
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—		—
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2023: 1,986,904,170; 2022: 1,986,519,278	24,488		24,709
Common shares held in treasury, at cost — Shares: 2023: 247,957,371; 2022: 248,724,257	(15,307)		(15,229)
Earnings employed in the business	35,868		35,257
Accumulated other comprehensive income (loss)	(8,039)		(8,051)
Total Abbott Shareholders’ Investment	37,010		36,686
Noncontrolling Interests in Subsidiaries	222		219
Total Shareholders’ Investment	37,232		36,905
	$	73,794	$	74,438

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)

Three Months Ended March 31


2022

2021
Common Shares:

Balance at January 1

Shares: 2022: 1,985,273,421; 2021: 1,981,156,896

$
24,470

$
24,145
Issued under incentive stock programs




Shares: 2022: 251,632; 2021: 1,048,595

14

47
Share-based compensation

324

304
Issuance of restricted stock awards

(504)

(473)
Balance at March 31




Shares: 2022: 1,985,525,053; 2021: 1,982,205,491

$
24,304

$
24,023

Common Shares Held in Treasury:

Balance at January 1

Shares: 2022: 221,191,228; 2021: 209,926,622

$
(11,822)

$
(10,042)
Issued under incentive stock programs




Shares: 2022: 4,144,476; 2021: 4,818,787

223

231
Purchased


Shares: 2022: 17,536,012; 2021: 277,508

(2,127)

(34)
Balance at March 31




Shares: 2022: 234,582,764; 2021: 205,385,343

$
(13,726)

$
(9,845)

Earnings Employed in the Business:

Balance at January 1

$
31,528

$
27,627
Net earnings

2,447

1,793
Cash dividends declared on common shares (per share — 2022: $0.47; 2021: $0.45)

(826)

(803)
Effect of common and treasury share transactions

146

52
Balance at March 31

$
33,295

$
28,669

Accumulated Other Comprehensive Income (Loss):

Balance at January 1

$
(8,374)

$
(8,946)
Other comprehensive income (loss)

(100)

(339)
Balance at March 31

$
(8,474)

$
(9,285)

Noncontrolling Interests in Subsidiaries:

Balance at January 1

$
222

$
219
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases

8

7
Balance at March 31

$
230

$
226


	Three Months Ended March 31
	2023		2022
Common Shares:
Balance at January 1
Shares: 2023: 1,986,519,278; 2022: 1,985,273,421	$	24,709	$	24,470
Issued under incentive stock programs
Shares: 2023: 384,892; 2022: 251,632	16		14
Share-based compensation	296		324
Issuance of restricted stock awards	(533)		(504)
Balance at March 31
Shares: 2023: 1,986,904,170; 2022: 1,985,525,053	$	24,488	$	24,304

Common Shares Held in Treasury:
Balance at January 1
Shares: 2023: 248,724,257; 2022: 221,191,228	$	(15,229)	$	(11,822)
Issued under incentive stock programs
Shares: 2023: 3,933,165; 2022: 4,144,476	242		223
Purchased
Shares: 2023: 3,166,279; 2022: 17,536,012	(320)		(2,127)
Balance at March 31
Shares: 2023: 247,957,371; 2022: 234,582,764	$	(15,307)	$	(13,726)

Earnings Employed in the Business:
Balance at January 1	$	35,257	$	31,528
Net earnings	1,318		2,447
Cash dividends declared on common shares (per share — 2023: $0.51; 2022: $0.47)	(890)		(826)
Effect of common and treasury share transactions	183		146
Balance at March 31	$	35,868	$	33,295

Accumulated Other Comprehensive Income (Loss):
Balance at January 1	$	(8,051)	$	(8,374)
Other comprehensive income (loss)	12		(100)
Balance at March 31	$	(8,039)	$	(8,474)

Noncontrolling Interests in Subsidiaries:
Balance at January 1	$	219	$	222
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases	3		8
Balance at March 31	$	222	$	230

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

~~(Unaudited)~~

(Unaudited)

(dollars in millions)

Three Months Ended March 31

2022

2021
Cash Flow From (Used in) Operating Activities:

Net earnings

$
2,447

$
1,793
Adjustments to reconcile net earnings to net cash from operating activities —

Depreciation

311

425
Amortization of intangible assets

512

509
Share-based compensation

305

288
Trade receivables

(751)

165
Inventories

(554)

(537)
Other, net

(205)

(6)
Net Cash From Operating Activities

2,065

2,637

Cash Flow From (Used in) Investing Activities:

Acquisitions of property and equipment

(321)

(397)
Acquisitions of businesses and technologies, net of cash acquired

—

(15)
Sales (purchases) of other investment securities, net

(41)

(14)
Other

2

4
Net Cash (Used in) Investing Activities

(360)

(422)

Cash Flow From (Used in) Financing Activities:

Net borrowings (repayments) of short-term debt and other

8

24
Repayments of long-term debt

(751)

(2)
Purchases of common shares

(2,307)

(275)
Proceeds from stock options exercised

59

86
Dividends paid

(832)

(800)
Net Cash (Used in) Financing Activities

(3,823)

(967)

Effect of exchange rate changes on cash and cash equivalents

(6)

(32)

Net Increase (Decrease) in Cash and Cash Equivalents

(2,124)

1,216
Cash and Cash Equivalents, Beginning of Year

9,799

6,838
Cash and Cash Equivalents, End of Period

$
7,675

$
8,054


	Three Months Ended March 31
	2023		2022
Cash Flow From (Used in) Operating Activities:
Net earnings	$	1,318	$	2,447
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation	315		311
Amortization of intangible assets	491		512
Share-based compensation	281		305
Trade receivables	233		(751)
Inventories	(419)		(554)
Other, net	(1,076)		(205)
Net Cash From Operating Activities	1,143		2,065

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(380)		(321)


Sales (purchases) of other investment securities, net	(86)		(41)
Other	4		2
Net Cash From (Used in) Investing Activities	(462)		(360)

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other	(42)		8

Repayments of long-term debt	—		(751)
Purchases of common shares	(540)		(2,307)
Proceeds from stock options exercised	62		59
Dividends paid	(890)		(832)
Net Cash From (Used in) Financing Activities	(1,410)		(3,823)

Effect of exchange rate changes on cash and cash equivalents	8		(6)

Net Increase (Decrease) in Cash and Cash Equivalents	(721)		(2,124)
Cash and Cash Equivalents, Beginning of Year	9,882		9,799
Cash and Cash Equivalents, End of Period	$	9,161	$	7,675

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, ~~2022~~

~~(Unaudited)~~

2023

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, ~~2021.~~2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recent Adopted Accounting Standards

In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has 4four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The following ~~table provides~~tables provide detail by sales category:

Three Months Ended March 31, 2022

Three Months Ended March 31, 2021
(in millions)

U.S.

Int’l

Total

U.S.

Int’l

Total
Established Pharmaceutical Products —












Key Emerging Markets

$
—

$
902

$
902

$
—

$
821

$
821
Other

—

245

245

—

249

249
Total

—

1,147

1,147

—

1,070

1,070
Nutritionals —

Pediatric Nutritionals

338

509

847

508

558

1,066
Adult Nutritionals

339

708

1,047

328

642

970
Total

677

1,217

1,894

836

1,200

2,036
Diagnostics —

Core Laboratory

268

916

1,184

271

911

1,182
Molecular

172

248

420

175

272

447
Point of Care

91

37

128

92

37

129
Rapid Diagnostics

2,210

1,344

3,554

1,103

1,153

2,256
Total

2,741

2,545

5,286

1,641

2,373

4,014
Medical Devices —

Rhythm Management

248

276

524

241

278

519
Electrophysiology

216

269

485

179

252

431
Heart Failure

167

54

221

145

49

194
Vascular

209

410

619

219

416

635
Structural Heart

190

221

411

169

208

377
Neuromodulation

143

36

179

145

39

184
Diabetes Care

343

783

1,126

253

727

980
Total

1,516

2,049

3,565

1,351

1,969

3,320

Other

3

—

3

10

6

16

Total

$
4,937

$
6,958

$
11,895

$
3,838

$
6,618

$
10,456


	Three Months Ended March 31, 2023						Three Months Ended March 31, 2022
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	912	$	912	$	—	$	906	$	906
Other	—		277		277		—		241		241
Total	—		1,189		1,189		—		1,147		1,147
Nutritionals —
Pediatric Nutritionals	459		465		924		338		509		847
Adult Nutritionals	353		690		1,043		339		708		1,047
Total	812		1,155		1,967		677		1,217		1,894
Diagnostics —
Core Laboratory	289		893		1,182		268		916		1,184
Molecular	47		100		147		172		248		420
Point of Care	93		41		134		91		37		128
Rapid Diagnostics	906		319		1,225		2,181		1,344		3,525
Total	1,335		1,353		2,688		2,712		2,545		5,257
Medical Devices —
Rhythm Management	260		267		527		248		276		524
Electrophysiology	238		267		505		216		269		485
Heart Failure	218		63		281		196		54		250
Vascular	218		399		617		209		410		619
Structural Heart	210		251		461		190		221		411
Neuromodulation	155		41		196		143		36		179
Diabetes Care	479		834		1,313		343		783		1,126
Total	1,778		2,122		3,900		1,545		2,049		3,594

Other	3		—		3		3		—		3

Total	$	3,928	$	5,819	$	9,747	$	4,937	$	6,958	$	11,895

Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.

~~Table of Contents~~

~~Note 2 — Revenue (Continued)~~

Remaining Performance Obligations

As of March 31, ~~2022,~~2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately ~~$3.8~~$4.1 billion in the Diagnostics segment and approximately ~~$428~~$450 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 1617 percent over the subsequent 12 months and the remainder thereafter.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 3 — Revenue (Continued)

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Changes in the contract liabilities during the period are as follows:

(in millions)

Contract Liabilities:

Balance at December 31, 2021

$
520
Unearned revenue from cash received during the period

171
Revenue recognized related to contract liability balance

(178)
Balance at March 31, 2022

$
513


(in millions)
Contract Liabilities:
Balance at December 31, 2022	$	500
Unearned revenue from cash received during the period	122
Revenue recognized related to contract liability balance	(93)
Balance at March 31, 2023	$	529

Note 34 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended March 31, 2023 and 2022 were $1.313 billion and ~~2021 were~~ $2.438 billion, ~~and $1.785 billion,~~ respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2023 includes $282 million of pension contributions and the payment of cash taxes of approximately $122 million. The first three months of 2022 includes $334 million of pension contributions and the payment of cash taxes of approximately $195 million. ~~The first three months of 2021 includes $16 million of pension contributions and the payment of cash taxes of approximately $270 million.~~

~~Table of Contents~~

~~Note 3 — Supplemental Financial Information (Continued)~~

The following summarizes the activity for the first three months of ~~2022~~2023 related to the allowance for doubtful accounts as of March 31, ~~2022:~~

2023:

(in millions)

Allowance for Doubtful Accounts:

Balance at December 31, 2021

$
313
Provisions/charges to income

3
Amounts charged off and other deductions

(15)
Balance at March 31, 2022

$
301


(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2022	$	262
Provisions/charges to income	8
Amounts charged off and other adjustments	2
Balance at March 31, 2023	$	272

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 4 — Supplemental Financial Information (Continued)

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of March 31, ~~2022~~2023 and December 31, ~~2021~~2022 are as follows:

March 31,

December 31,
(in millions)

2022

2021
Long-term Investments:

Equity securities

$
703

$
748
Other

60

68
Total

$
763

$
816


(in millions)	March 31, 2023		December 31, 2022
Long-term Investments:
Equity securities	$	565	$	558
Other	211		208
Total	$	776	$	766

The ~~decrease~~increase in Abbott’s long-term investments as of March 31, ~~2022~~2023 versus the balance as of December 31, ~~2021~~2022 primarily relates to ~~a decrease~~an increase in the value of ~~investments~~securities held in a rabbi ~~trust.~~

trust and additional investments,

partially offset by equity method investment losses.

Abbott’s equity securities as of March 31, ~~2022,~~2023, include ~~$357~~$305 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of March 31, ~~2022~~2023 with a carrying value of ~~$244~~$162 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of ~~$92~~approximately $88 million that do not have a readily determinable fair value.

~~Table of Contents~~

Note 45 — Changes inIn Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended March 31

Cumulative Gains (Losses)

Cumulative Foreign

Net Actuarial (Losses) and

on Derivative Instruments

Currency Translation

Prior Service (Costs) and

Designated as Cash Flow

Adjustments

Credits

Hedges
(in millions)

2022

2021

2022

2021

2022

2021
Balance at January 1

$
(5,839)

$
(4,859)

$
(2,670)

$
(3,871)

$
135

$
(216)
Other comprehensive income (loss) before reclassifications

(106)

(536)

17

22

(34)

96
Amounts reclassified from accumulated other comprehensive income

—

—

45

63

(22)

16
Net current period comprehensive income (loss)

(106)

(536)

62

85

(56)

112
Balance at March 31

$
(5,945)

$
(5,395)

$
(2,608)

$
(3,786)

$
79

$
(104)


	Three Months Ended March 31
	Cumulative Foreign Currency Translation (Loss) Adjustments				Net Actuarial (Losses) and Prior Service (Costs) and Credits				Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges and Other
(in millions)	2023		2022		2023		2022		2023		2022
Balance at January 1	$	(6,733)	$	(5,839)	$	(1,493)	$	(2,670)	$	175	$	135
Other comprehensive income (loss) before reclassifications	139		(106)		2		17		(42)		(34)
Amounts reclassified from accumulated other comprehensive income	—		—		—		45		(87)		(22)
Net current period comprehensive income (loss)	139		(106)		2		62		(129)		(56)
Balance at March 31	$	(6,594)	$	(5,945)	$	(1,491)	$	(2,608)	$	46	$	79

~~(Income) loss~~

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 5 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)

Reclassified amounts ~~reclassified from accumulated other comprehensive income related to~~for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 1112 for additional details.

Note 56 — Goodwill and Intangible Assets

The total amount of goodwill reported was ~~$23.2~~$22.9 billion at March 31, ~~2022~~2023 and $22.8 billion at December 31, ~~2021.~~2022. Foreign currency translation adjustments ~~decreased~~increased goodwill by approximately ~~$50~~$128 million in the first three months of ~~2022.~~2023. The amount of goodwill related to reportable segments at March 31, ~~2022~~2023 was ~~$2.8~~$2.7 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, ~~$3.7~~$3.5 billion for the Diagnostic Products segment, and $16.4 billion for the Medical Devices segment. There was 0no reduction of goodwill relating to impairments in the first three months of ~~2022.~~

2023.

The gross amount of amortizable intangible assets, primarily product rights and technology, was ~~$27.7~~$27.4 billion and $27.2 billion as of March 31, ~~2022~~2023 and December 31, ~~2021 and accumulated~~2022, respectively. Accumulated amortization was ~~$16.4~~$18.2 billion and $17.6 billion as of March 31, ~~2022~~2023 and ~~$15.9 billion as of~~ December 31, ~~2021.~~2022, respectively. Foreign currency translation adjustments increased intangible assets by $3$43 million in the first three months of ~~2022.~~2023. Abbott’s estimated annual amortization expense for intangible assets is approximately ~~$2.1 billion in 2022,~~ $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025, ~~and $1.6~~$1.5 billion in ~~2026.~~

2026 and $1.2 billion in 2027.

Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately ~~$919~~$807 million as of March 31, ~~2022~~2023 and December 31, ~~2021.~~

2022.

~~Table of Contents~~

Note 67 — Restructuring Plans

~~On May 27, 2021,~~

In 2022 and 2023, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of products sold. The charge recognized in the second quarter included fixed asset write-downs of $80 million, inventory-related charges of $248 million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.

In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly, particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in thesecond half of 2021, Abbott sold approximately $181 million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was recorded in the second quarter or Abbott settled with the counterparty in the second half of 2021.

~~The following summarizes the activity related to this restructuring action and the status of the related accruals as of March 31, 2022:~~

Inventory-

Related

Fixed Asset

Other Exit

(in millions)

Charges

Write-Downs

Costs

Total
Restructuring charges recorded in 2021

$
248

$
80

$
113

$
441
Payments

—

—

(90)

(90)
Other non-cash

(248)

(80)

—

(328)
Accrued balance at December 31, 2021

—

—

23

23
Payments and other adjustments

—

—

(3)

(3)
Accrued balance at March 31, 2022

$
—

$
—

$
20

$
20

~~In 2021, Abbott management approved~~various plans to streamline operations in order to reduce costs and improve efficiencies in~~Abbott’s diagnostics, established pharmaceuticals, nutritional, and~~ its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the first three months of 2023, Abbott recorded ~~employee-related~~employee related severance and other charges ofapproximately ~~$68~~$17 million, ~~in 2021~~ of whichapproximately ~~$16~~$6 million was recorded in Cost of products sold, ~~approximately $4 million was recorded in Research and development,~~ and approximately ~~$48~~$11 million was recorded in Selling, general and administrative ~~expense.~~

expenses.

The following summarizes the activity ~~for~~related to these ~~restructurings:~~

(in millions)

Restructuring charges

$
68
Payments and other adjustments

(7)
Accrued balance at December 31, 2021

61
Payments and other adjustments

(16)
Accrued balance at March 31, 2022

$
45

restructuring actions and the status of the related accruals as of March 31, 2023:


(in millions)
Accrued balance at December 31, 2022	$	228
Restructuring charges in 2023	17
Payments and other adjustments	(61)
Accrued balance at March 31, 2023	$	184

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 78 — Incentive Stock Programs

In the first three months of ~~2022,~~2023, Abbott granted ~~2,594,059~~1,887,093 stock options, ~~514,148~~445,278 restricted stock awards and ~~5,303,072~~4,761,433 restricted stock units under its incentive stock program. At March 31, ~~2022,~~2023, approximately 8674 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, ~~2022~~2023 is as follows:

Outstanding

Exercisable
Number of shares

29,479,237

23,547,781
Weighted average remaining life (years)

5.9

5.1
Weighted average exercise price

$
69.87

$
59.23
Aggregate intrinsic value (in millions)

$
1,445

$
1,397


	Outstanding		Exercisable
Number of shares	29,760,644		25,107,006
Weighted average remaining life (years)	5.4		4.7
Weighted average exercise price	$	73.33	$	65.76
Aggregate intrinsic value (in millions)	$	947	$	946

The total unrecognized share-based compensation cost at March 31, ~~2022~~2023 amounted to approximately ~~$825~~$760 million, which is expected to be recognized over the next three years.

Note 89 — Debt and Lines of Credit

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes ~~due 2022~~ upon maturity.

Note 910 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling ~~$8.5~~$7.1 billion at March 31, ~~2022~~2023 and ~~$8.6~~$7.7 billion at December 31, ~~2021~~2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, ~~2022~~2023 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, Abbott held the gross notional ~~amount~~amounts of ~~$12.2~~$11.4 billion and $12.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately ~~$491~~$451 million and ~~$521~~$446 million as of March 31, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $2.9 billion at March 31, ~~2022~~2023 and December 31, ~~2021~~2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 910 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, ~~2022~~2023 and December 31, ~~2021:~~

2022:

Fair Value - Assets

Fair��Value - Liabilities

March 31,

Dec. 31,

March 31,

Dec. 31,


(in millions)

2022

2021

Balance Sheet Caption

2022

2021

Balance Sheet Caption
Interest rate swaps designated as fair value hedges

$
—

$
87

Deferred income taxes and other assets

$
34

$
—

Post-employment obligations, deferred income taxes and other long-term liabilities
Foreign currency forward exchange contracts:

Hedging instruments

204

222

Prepaid expenses and other receivables

183

65

Other accrued liabilities
Others not designated as hedges

149

70

Prepaid expenses and other receivables

93

32

Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary

—

—

n/a

491

521

Long-term debt

$
353

$
379

$
801

$
618


	Fair Value - Assets					Fair Value - Liabilities
(in millions)	March 31, 2023		December 31, 2022		Balance Sheet Caption	March 31, 2023		December 31, 2022		Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current	$	—	$	—	Deferred income taxes and other assets	$	126	$	136	Post-employment obligations, deferred income taxes and other long-term liabilities
Current	—		—		Prepaid expenses and other receivables	21		20		Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments	76		304		Prepaid expenses and other receivables	139		96		Other accrued liabilities
Others not designated as hedges	78		108		Prepaid expenses and other receivables	96		130		Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	451		446		Long-term debt
	$	154	$	412		$	833	$	828

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, ~~2022~~2023 and ~~2021.~~

2022.

Gain (loss) Recognized in

Income (expense) and

Other Comprehensive

Gain (loss) Reclassified

Income (loss)

into Income

(in millions)

2022

2021

2022

2021

Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges

$
(49)

$
134

$
27

$
(23)

Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary

30

35

—

—

n/a
Interest rate swaps designated as fair value hedges

n/a

n/a

(121)

(69)

Interest expense


	Gain (loss) Recognized in Other Comprehensive Income (loss)				Income (expense) and Gain (loss) Reclassified into Income
	Three Months Ended March 31				Three Months Ended March 31
(in millions)	2023		2022		2023		2022		Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges	$	(63)	$	(49)	$	126	$	27	Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary	(5)		30		—		—		n/a
Interest rate swaps designated as fair value hedges	n/a		n/a		9		(121)		Interest expense

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

Losses of ~~$51~~$103 million and ~~gains of $49~~$51 million were recognized in the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

~~Table of Contents~~

~~Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)~~

The carrying values and fair values of certain financial instruments as of March 31, ~~2022~~2023 and December 31, ~~2021~~2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

March 31, 2022

December 31, 2021


Carrying

Fair

Carrying

Fair
(in millions)

Value

Value

Value

Value
Long-term Investment Securities:

Equity securities

$
703

$
703

$
748

$
748
Other

60

60

68

68
Total long-term debt

(17,090)

(18,704)

(18,050)

(21,152)
Foreign Currency Forward Exchange Contracts:

Receivable position

353

353

292

292
(Payable) position

(276)

(276)

(97)

(97)
Interest Rate Hedge Contracts:

Receivable position

—

—

87

87
(Payable) position

(34)

(34)

—

—


	March 31, 2023				December 31, 2022
(in millions)	Carrying Value		Fair Value		Carrying Value		Fair Value
Long-term Investment Securities:
Equity securities	$	565	$	565	$	558	$	558
Other	211		211		208		208
Total Long-term Debt	(16,900)		(16,927)		(16,773)		(16,313)
Foreign Currency Forward Exchange Contracts:
Receivable position	154		154		412		412
(Payable) position	(235)		(235)		(226)		(226)
Interest Rate Hedge Contracts:

(Payable) position	(147)		(147)		(156)		(156)

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement

Quoted

Significant

Prices in

Other

Significant

Outstanding

Active

Observable

Unobservable
(in millions)

Balances

Markets

Inputs

Inputs
March 31, 2022:

Equity securities

$
367

$
367

$
—

$
—
Foreign currency forward exchange contracts

353

—

353

—
Total Assets

$
720

$
367

$
353

$
—

Fair value of hedged long-term debt

$
2,805

$
—

$
2,805

$
—
Interest rate swap derivative financial instruments

34

—

34

—
Foreign currency forward exchange contracts

276

—

276

—
Contingent consideration related to business combinations

134

—

—

134
Total Liabilities

$
3,249

$
—

$
3,115

$
134

December 31, 2021:

Equity securities

$
402

$
402

$
—

$
—
Interest rate swap derivative financial instruments

87

—

87

—
Foreign currency forward exchange contracts

292

—

292

—
Total Assets

$
781

$
402

$
379

$
—

Fair value of hedged long-term debt

$
2,926

$
—

$
2,926

$
—
Foreign currency forward exchange contracts

97

—

97

—
Contingent consideration related to business combinations

130

—

—

130
Total Liabilities

$
3,153

$
—

$
3,023

$
130


			Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
March 31, 2023:
Equity securities	$	315	$	315	$	—	$	—
Foreign currency forward exchange contracts	154		—		154		—
Total Assets	$	469	$	315	$	154	$	—

Fair value of hedged long-term debt	$	2,720	$	—	$	2,720	$	—
Interest rate swap derivative financial instruments	147		—		147		—
Foreign currency forward exchange contracts	235		—		235		—
Contingent consideration related to business combinations	133		—		—		133
Total Liabilities	$	3,235	$	—	$	3,102	$	133

December 31, 2022:
Equity securities	$	307	$	307	$	—	$	—

Foreign currency forward exchange contracts	412		—		412		—
Total Assets	$	719	$	307	$	412	$	—

Fair value of hedged long-term debt	$	2,691	$	—	$	2,691	$	—
Interest rate swap derivative financial instruments	156		—		156		—
Foreign currency forward exchange contracts	226		—		226		—
Contingent consideration related to business combinations	130		—		—		130
Total Liabilities	$	3,203	$	—	$	3,073	$	130

~~Table of Contents~~

~~Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)~~

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.

Note 1011 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 11 — Litigation and Environmental Matters (Continued)

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately ~~$30~~$25 million to ~~$45~~$35 million. The recorded accrual balance at March 31, ~~2022~~2023 for these proceedings and exposures was approximately ~~$40~~$30 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 1112 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit Plans

Medical and Dental Plans

March 31,

March 31,

March 31,

March 31,
(in millions)

2022

2021

2022

2021

Service cost — benefits earned during the period

$
96

$
100

$
13

$
14
Interest cost on projected benefit obligations

76

62

10

8
Expected return on plan assets

(236)

(211)

(7)

(7)
Net amortization of:

Actuarial loss, net

59

81

5

7
Prior service cost (credit)

—

—

(6)

(7)
Net cost (credit)

$
(5)

$
32

$
15

$
15


	Defined Benefit Plans				Medical and Dental Plans
	Three Months Ended March 31				Three Months Ended March 31
(in millions)	2023		2022		2023		2022
Service cost - benefits earned during the period	$	60	$	96	$	9	$	13
Interest cost on projected benefit obligations	114		76		14		10
Expected return on plan assets	(242)		(236)		(6)		(7)
Net amortization of:
Actuarial loss, net	3		59		—		5
Prior service cost (credit)	—		—		(3)		(6)
Net cost (credit)	$	(65)	$	(5)	$	14	$	15

Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2023 and 2022, ~~and 2021, $334~~$282 million and ~~$16~~$334 million, respectively, were contributed to defined benefit plans. ~~Contributions made to post-employment medical and dental plans in~~In the first three months of 2023 and 2022, ~~were~~ $28 ~~million. NaN contributions were made~~million was contributed in each year to the post-employment medical and dental ~~plans in the first three months of 2021.~~

plans.

~~Table of Contents~~

Note 1213 — Taxes on Earnings

Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of ~~2022~~2023 and ~~2021,~~2022, taxes on earnings include approximately ~~$30~~$3 million and ~~$80~~$30 million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2023 and 2022, taxes on earnings also include approximately $22 million and $30 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately ~~$70~~$75 million to $80 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 1314 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories ~~physicians’ offices~~ and alternate-care testing sites. For segment reporting purposes, the Core ~~Laboratory~~Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2023

(Unaudited)

Note 1314 — Segment Information (Continued)

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the ~~condensed~~ consolidated financial statements.


	Net Sales to External Customers				Operating Earnings
	Three Months Ended March 31				Three Months Ended March 31
(in millions)	2023		2022		2023		2022
Established Pharmaceutical Products	$	1,189	$	1,147	$	300	$	242
Nutritional Products	1,967		1,894		380		251
Diagnostic Products	2,688		5,257		651		2,564
Medical Devices	3,900		3,594		1,078		1,083
Total Reportable Segments	9,744		11,892		2,409		4,140
Other	3		3
Net sales	$	9,747	$	11,895
Corporate functions and benefit plan costs					(77)		(114)
Net interest expense					(52)		(117)
Share-based compensation (a)					(281)		(305)
Amortization of intangible assets					(491)		(512)
Other, net (b)					54		(216)
Earnings before taxes					$	1,562	$	2,876

Three Months Ended March 31

Net Sales to

Operating

External Customers

Earnings
(in millions)

2022

2021

2022

2021
Established Pharmaceutical Products

$
1,147

$
1,070

$
242

$
169
Nutritional Products

1,894

2,036

251

467
Diagnostic Products

5,286

4,014

2,569

1,701
Medical Devices

3,565

3,320

1,078

1,007
Total Reportable Segments

11,892

10,440

4,140

3,344
Other

3

16

Net sales

$
11,895

$
10,456

Corporate functions and benefit plans costs

(114)

(114)
Net interest expense

(117)

(124)
Share-based compensation (a)

(305)

(288)
Amortization of intangible assets

(512)

(509)
Other, net (b)

(216)

(266)
Earnings before taxes

$
2,876

$
2,043

~~(a)~~
Notes:			2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
(a)			Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)

~~(b)~~

Other, net for the three months ended March 31, 2022 includes $120 million of charges related to a voluntary recall within the Nutritional Products segment. Other, net for the three months ended March 31, 2021 includes net costs related to certain litigation. Other, net for the three months ended March 31, 2022 and 2021 also includes integration costs associated with the acquisitions of St. Jude Medical and Alere Inc., and restructuring charges.

Note 15 — Subsequent Event

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of approximately $850 million. The acquisition was funded with cash on hand. CSI sells an atherectomy system used in treating peripheral and coronary artery disease. The acquisition adds complementary technologies to Abbott’s portfolio of vascular device offerings. The transaction will be accounted for as a business combination. Abbott has begun the process of measuring, as of the acquisition date, the acquired assets and assumed liabilities. Preliminary purchase price allocation estimates will be disclosed in Abbott’s Form 10-Q for the period ending June 30, 2023.

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review -— Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

The following ~~table details~~tables detail sales by reportable segment for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.


	Net Sales to External Customers
(in millions)	Three Months Ended March 31, 2023		Three Months Ended March 31, 2022		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	1,189	$	1,147	3.7	%	(7.4)	%	11.1	%
Nutritional Products	1,967		1,894		3.8		(3.9)		7.7
Diagnostic Products	2,688		5,257		(48.9)		(1.8)		(47.1)
Medical Devices	3,900		3,594		8.5		(3.9)		12.4
Total Reportable Segments	9,744		11,892		(18.1)		(3.3)		(14.8)
Other	3		3		n/m		n/m		n/m
Net Sales	$	9,747	$	11,895	(18.1)		(3.3)		(14.8)

Total U.S.	$	3,928	$	4,937	(20.4)		—		(20.4)

Total International	$	5,819	$	6,958	(16.4)		(5.7)		(10.7)


Notes:			The Acelis Connected Health business was internally transferred from Diagnostic Products to Medical Devices on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Diagnostic Products to Medical Devices.
			In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
			n/m = Percent change is not meaningful

Net Sales to External Customers


Three Months

Three Months






Ended

Ended

Impact of

Total Change

March 31,

March 31,

Total

Foreign

Excl. Foreign

(in millions)

2022

2021

Change

Exchange

Exchange

Established Pharmaceutical Products

$
1,147

$
1,070

7.1
%
(6.3)
%
13.4
%
Nutritional Products

1,894

2,036

(7.0)

(2.6)

(4.4)

Diagnostic Products

5,286

4,014

31.7

(3.4)

35.1

Medical Devices

3,565

3,320

7.4

(4.1)

11.5

Total Reportable Segments

11,892

10,440

13.9

(3.8)

17.7

Other

3

16

(85.8)

—

(85.8)

Net Sales

$
11,895

$
10,456

13.8

(3.7)

17.5

Total U.S.

$
4,937

$
3,838

28.6

—

28.6

Total International

$
6,958

$
6,618

5.1

(6.0)

11.1

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

The ~~17.5~~14.8 percent ~~increase~~decrease in total net sales during the first three months of ~~2022,~~2023, excluding the impact of foreign exchange, reflected the decrease in demand for Abbott’s rapid ~~diagnostics~~diagnostic tests to detect COVID-19, ~~as well as growth in Abbott’s Medical Devices and Established Pharmaceutical Products segments~~ partially offset by ~~lower Nutritional sales. During the first quarter of 2022,~~higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately ~~$3.3 billion led by combined sales of approximately $3.0 billion related to Abbott’s BinaxNOW~~^®~~, Panbio~~^®~~, and ID NOW~~^® ~~rapid testing platforms. During~~$730 million during the first quarter of ~~2021, Abbott’s COVID-19 testing-related sales totaled~~2023 and approximately ~~$2.2~~$3.3 billion ~~led by combined sales~~during the first quarter of ~~approximately $1.8 billion related to Abbott’s BinaxNOW, Panbio, and ID NOW rapid testing platforms.~~2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased ~~3.9~~4.9 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased ~~7.7~~9.4 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first quarter as the relatively stronger U.S. dollar decreased total international sales by ~~6.0~~5.7 percent and total sales by ~~3.7~~3.3 percent.

Due to the unpredictability of ~~the duration and impact of the current~~demand for COVID-19 ~~pandemic,~~tests, the future extent to which ~~the~~ COVID-19 ~~pandemic~~ will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.

Table of Contents

The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.

Impact of

Total Change

March 31,

March 31,

Total

Foreign

Excl. Foreign

(in millions)

2022

2021

Change

Exchange

Exchange

Established Pharmaceutical Products —











Key Emerging Markets

$
902

$
821

9.8
%
(7.3)
%
17.1
%
Other Emerging Markets

245

249

(1.7)

(2.9)

1.2

Nutritionals —

International Pediatric Nutritionals

509

558

(8.8)

(3.4)

(5.4)

U.S. Pediatric Nutritionals

338

508

(33.6)

—

(33.6)

International Adult Nutritionals

708

642

10.3

(5.3)

15.6

U.S. Adult Nutritionals

339

328

3.7

—

3.7

Diagnostics —

Core Laboratory

1,184

1,182

0.1

(4.1)

4.2

Molecular

420

447

(5.9)

(2.9)

(3.0)

Point of Care

128

129

(0.6)

(1.0)

0.4

Rapid Diagnostics

3,554

2,256

57.5

(3.3)

60.8

Medical Devices —

Rhythm Management

524

519

1.0

(3.2)

4.2

Electrophysiology

485

431

12.6

(4.2)

16.8

Heart Failure

221

194

14.2

(2.0)

16.2

Vascular

619

635

(2.6)

(3.6)

1.0

Structural Heart

411

377

9.1

(4.7)

13.8

Neuromodulation

179

184

(3.1)

(1.6)

(1.5)

Diabetes Care

1,126

980

14.9

(5.5)

20.4


(in millions)	March 31, 2023		March 31, 2022		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange
Established Pharmaceutical Products —
Key Emerging Markets	$	912	$	906	0.7	%	(7.6)	%	8.3	%
Other Emerging Markets	277		241		15.0		(6.8)		21.8

Nutritionals —
International Pediatric Nutritionals	465		509		(8.6)		(4.7)		(3.9)
U.S. Pediatric Nutritionals	459		338		36.1		—		36.1
International Adult Nutritionals	690		708		(2.6)		(7.0)		4.4
U.S. Adult Nutritionals	353		339		3.9		—		3.9

Diagnostics —
Core Laboratory	1,182		1,184		(0.2)		(5.3)		5.1
Molecular	147		420		(65.0)		(1.0)		(64.0)
Point of Care	134		128		4.7		(1.0)		5.7
Rapid Diagnostics	1,225		3,525		(65.3)		(0.8)		(64.5)

Medical Devices —
Rhythm Management	527		524		0.4		(3.6)		4.0
Electrophysiology	505		485		3.9		(4.9)		8.8
Heart Failure	281		250		12.4		(1.2)		13.6
Vascular	617		619		(0.2)		(4.1)		3.9
Structural Heart	461		411		12.2		(4.2)		16.4
Neuromodulation	196		179		9.4		(1.8)		11.2
Diabetes Care	1,313		1,126		16.6		(4.4)		21.0

Table of Contents

Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased ~~17.1~~8.3 percent in the first three months of 2023, led by ~~double-digit~~ growth in several countries, including Brazil, China and southeast Asia, and across several therapeutic areas, including ~~gastroenterology,~~cardio-metabolic, respiratory, and central nervous system/pain ~~management, and respiratory products.~~management. Other Emerging Markets, excluding the effect of foreign exchange, increased by ~~1.2 percent.~~

~~International Pediatric Nutritional sales, excluding~~21.8 percent in the ~~effect~~first three months of 2023.

Excluding the impact of foreign exchange, ~~decreased 5.4 percent. The decrease reflects lower~~total Nutritional Products sales ~~due to challenging market dynamics~~ in the infant category in Greater China partially offset by higher volumes sold in various countries in Southeast Asia, Latin America and the Middle East. International Adult Nutritional sales, excluding the effectfirst three months of ~~foreign exchange,~~2023 increased ~~15.6~~7.7 percent ~~and U.S. Adult Nutritional sales increased 3.7 percent, reflecting continued growth of the Ensure~~^® ~~and Glucerna~~^® ~~brands in several countries including the U.S.~~

. In

In U.S. Pediatric Nutritionals, ~~Abbott initiated a voluntary recall~~the 36.1 percent increase in ~~February 2022~~sales in the first three months of ~~certain infant powder formula products manufactured at one of its U.S. facilities and stopped production at the facility. The 33.6 percent decrease in U.S. Pediatric Nutritional sales reflects~~2023 reflects the impact of the unfavorable effects of the voluntary recall ~~and production stoppage partially offset by increased demand for Abbott’s Pedialyte~~^® ~~and PediaSure~~^® ~~products. U.S. sales~~ of certain infant ~~powder formulas were $59 million~~formula products in the first quarter of 2022, ~~and $288 million~~partially offset by a decrease in 2023 Pedialyte® sales. Excluding the effect of foreign exchange, the 3.9 percent decrease in International Pediatric Nutritional sales in the first ~~quarter~~three months of ~~2021. Abbott is working with~~2023 primarily reflects the impact of exiting the pediatric nutrition business in China, partially offset by growth in several other markets.

Excluding the effect of foreign exchange, the increases of 3.9 percent in U.S. ~~Food~~Adult Nutritionals and ~~Drug Administration (FDA) on corrective actions and enhancements so that operations at~~4.4 percent in International Adult Nutritionals in the facility can be restarted. Abbott cannot predict when manufacturing at the facility will restart. Abbott is also working to bring infant powder formula to the U.S. from its FDA-regulated facility in Europe and to increase production at other U.S. manufacturing plants.

first three months of 2023 were led by growth of Ensure®

products.

~~Table of Contents~~

The ~~35.1~~47.1 percent ~~increase~~decrease in Diagnostic Products sales in the first three months of 2023, excluding the impact of foreign exchange, was driven by lower demand for ~~Abbott’s portfolio of~~ COVID-19 ~~tests in~~tests. In Rapid Diagnostics, sales decreased 64.5 percent in the first three months of 2023, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first three months of 2023 and ~~growth in routine diagnostic testing in Core Laboratory~~2022, Rapid Diagnostics COVID-19 testing-related sales were $704 million and ~~Molecular Diagnostics.~~ $3.0 billion, respectively. In the first three months of 2023, Rapid Diagnostics sales increased 5.1 percent, excluding COVID-19 testing-related sales, and increased 8.0 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Core Laboratory Diagnostics, sales increased ~~4.2~~5.1 percent in the first three months of 2023, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing ~~from the continued roll-out of the Alinity~~^® ~~platform~~performed in hospitals and ~~an expanded menu of tests~~other laboratories, partially offset by lower test sales ~~of Abbott’s laboratory-based tests~~ for the detection of COVID-19 IgG and IgM ~~antibodies, which determine if someone was previously infected with the COVID-19 virus.~~antibodies. In the first three months of ~~2022~~2023 and ~~2021,~~2022, Core Laboratory Diagnostics COVID-19 ~~IgG and IgM antibody~~ testing-related sales ~~on Abbott’s ARCHITECT~~^® ~~and Alinity i platforms~~ were ~~$28~~$6 million and ~~$54~~$28 million, respectively. In the first three months of ~~2022,~~2023, Core Laboratory Diagnostics sales increased ~~2.4~~1.7 percent, excluding COVID-19 testing-related sales, and increased ~~6.6~~7.1 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

The ~~3.0~~64.0 percent decrease in Molecular Diagnostics sales in the first three months of 2023, excluding the effect of foreign exchange, was driven by lower demand for ~~Abbott’s~~ laboratory-based molecular tests for COVID-19 ~~on its m2000~~^® ~~platform partially offset by growth~~as well as lower demand for respiratory testing compared to significantly higher-than-usual demand in the ~~base business from increased routine molecular testing and an expanded menu~~first quarter of ~~tests.~~ 2022. In the first three months of ~~2022~~2023 and ~~2021,~~2022, Molecular Diagnostics COVID-19 testing-related sales were ~~$246~~$20 million and ~~$307~~$246 million, respectively. In the first three months of ~~2022,~~2023, Molecular Diagnostics sales ~~increased 24.8~~decreased 27.1 percent, excluding COVID-19 testing-related sales, and ~~increased 29.0~~decreased 24.8 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.

In Rapid Diagnostics, sales increased 60.8 percent, excluding the effect of foreign exchange, due to the demand for Abbott’s COVID-19 tests on its rapid testing platforms, including the Panbio system, the ID NOW platform, and the BinaxNOW COVID-19 Ag Card test. In the first three months of 2022 and 2021, Rapid Diagnostics COVID-19 testing-related sales were approximately $3.0 billion and $1.8 billion, respectively. In the first three months of 2022, Rapid Diagnostics sales increased 21.6 percent, excluding COVID-19 testing-related sales, and increased 23.5 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales. These increases reflect higher sales of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in other Rapid Diagnostics products.

Excluding the effect of foreign exchange, total Medical Devices sales grew ~~11.5~~12.4 percent ~~driven~~in the first three months of 2023, led by double-digit growth in Diabetes Care, ~~Electrophysiology,~~ Structural Heart, Heart Failure and ~~Heart Failure. Growth in~~Neuromodulation. Higher Diabetes Care sales ~~was~~were driven by continued growth of FreeStyle Libre^®, Abbott’s continuous glucose monitoring system, ~~internationally and~~ in the U.S. and internationally. FreeStyle Libre sales totaled ~~$995 million~~$1.2 billion in the first three months of ~~2022,~~2023, which reflected a ~~26.2~~25.4 percent increase, excluding the effect of foreign exchange, over the first three months of ~~2021~~2022 when FreeStyle Libre sales totaled ~~$827 million.~~

$1.0 billion.

~~While~~

During the first three months of 2023, procedure volumes increased across ~~Abbott’s~~the cardiovascular and neuromodulation ~~businesses were negatively impacted by elevated COVID-19 case rates early~~businesses. In Structural Heart, the 16.4 percent increase in ~~2022, overall volume trends improved as case rates declined in the second half of the first quarter. In Electrophysiology,~~sales, excluding the effect of foreign exchange, ~~the increase in procedure volumes also~~ reflects ~~the U.S. roll-out of Abbott’s EnSite™ X EP System with Ensite Omnipolar Technology (OT), a new cardiac mapping platform available~~an acceleration in the U.S., Japan and across Europe. In January 2022, Abbott announced FDA clearance for the EnSite X EP System with EnSite OT. The system leverages the Advisor™ HD Grid Catheter to provide a 360-degree viewgrowth of the ~~heart without regard to the orientation of the catheter in the heart.~~

MitraClip®

~~Growth in Structural Heart, excluding the effect of foreign exchange, was broad-based across several areas of the business,~~product along with contributions from recently launched products, including ~~Amplatzer~~^Amulet® ~~Amulet~~, Navitor® ~~Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage, an area in the heart where blood clots can form~~, and ~~MitraClip~~^TriClip®~~, Abbott’s market-leading device for the minimally invasive treatment of mitral regurgitation, a leaky heart valve.~~. In Vascular, the ~~1.0~~3.9 percent ~~growth~~increase in sales, excluding the impact of foreign exchange, during the first three months of 2023 primarily reflects double-digit growth in endovascular sales.

Table of Contents

In Electrophysiology, the 8.8 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher ~~endovascular~~procedure volumes in various European countries and the U.S. In Neuromodulation the 11.2 percent increase in sales, ~~partially offset~~excluding the effect of foreign exchange, was driven by the ~~negative effect~~recent launch of ~~lower average pricing~~the EternaTM rechargeable spinal cord stimulation system for ~~drug-eluting stents (DES) in~~ the ~~U.S. and a lag in the recovery~~treatment of ~~percutaneous coronary intervention case rates~~chronic pain along with market growth compared to ~~many other cardiovascular procedures.~~

the prior year period.

In ~~2022,~~the first three months of 2023, Medical Devices received various product approvals. In ~~February 2022,~~January 2023, Abbott ~~received FDA approval~~announced that the U.S. Food and Drug Administration (FDA) had approved Navitor, Abbott's second-generation transcatheter aortic valve implantation system to treat people with severe aortic stenosis who are at high or extreme risk for ~~an expanded indication for its CardioMEMS™ HF system, a small implantable sensor and remote~~open-heart surgery. In March 2023, Abbott's Freestyle Libre continuous glucose monitoring system ~~that can detect early warning signs of worsening heart failure.~~received U.S. FDA clearance for integration with automated insulin delivery systems. In ~~April 2022, Abbott announced FDA approval for its Aveir™ single-chamber leadless pacemaker for the treatment of patients in~~March 2023, the U.S. FDA approved Abbott's Epic® Max stented tissue valve to treat people with ~~slow heart rhythms.~~

aortic regurgitation or stenosis.

The gross profit margin percentage was 50.5 percent for the first quarter of 2023 compared to 53.8 percent for the first quarter of ~~2022 compared to 53.0 percent for~~2022. The decrease in the first quarter of ~~2021. The increase in the quarter~~2023 reflects the ~~effect~~unfavorable effects of ~~higher~~lower sales ~~volume~~ of COVID-19 ~~rapid~~ tests, ~~the impact of gross margin improvement initiatives, and the favorable impact of~~ foreign exchange, onand higher costs for various manufacturing inputs, partially offset by the impact in 2022 of the voluntary product recall in the Nutritional business and ~~higher inflation on various manufacturing inputs, commodities and distribution costs.~~

the impact in 2023 of gross margin improvement initiatives.

~~Table of Contents~~

Research and development (R&D) expenses ~~increased~~decreased $43 million, or ~~6.5~~6.2 percent, in the first quarter of ~~2022.~~2023 compared to the prior year. The ~~2022 increase~~decrease in R&D expenses in the first quarter of 2023 was primarily driven by ~~higher~~the timing of spending on various projects ~~to advance products in development partially offset by~~and the favorable impact of foreign exchange.

Selling, general and administrative expenses ~~were basically flat~~decreased $25 million, or 0.9 percent, in the first quarter of ~~2022~~2023 compared to the ~~first quarter of 2021. Higher~~prior year as higher selling and marketing spending to drive growth across various businesses was offset by the ~~nonrecurrence of certain 2021 litigation costs and the~~ favorable impact of foreign ~~exchange.~~

exchange and the nonrecurrence of 2022 expenses related to the product recall in the Nutritional segment.

Other (Income) Expense, net

Other income, net increased from ~~$61 million of income in the first quarter of 2021 to~~ $78 million of income in the first quarter of ~~2022. The increase~~2022 to $111 million of income in the first quarter ~~was primarily due to~~of 2023. The increase in the first quarter of 2023 reflects higher income in ~~2022~~2023 related to the non-service cost components of net pension and post-retirement medical benefit ~~costs partially offset by the change in earnings of equity method investments.~~

costs.

Interest Expense, net

Interest ~~expense,~~expense, net decreased $7$65 million in the first quarter of ~~2022 primarily~~2023 due to the impact of higher interest rates on interest income, inpartially offset by the ~~first quarter~~impact of ~~2022 and the repayment of debt in the first quarter of 2022.~~interest rate hedge contracts related to certain fixed-rate debt.

Taxes on Earnings

Table of Contents

Liquidity and Capital Resources March 31, ~~2022~~2023 Compared with December 31, ~~2021~~2022

~~Cash~~

The decrease in cash and cash equivalents ~~decreased~~ from ~~$9.8~~$9.9 billion at December 31, ~~2021~~2022 to ~~$7.7~~$9.2 billion at March 31, ~~2022 as cash used to fund share repurchases,~~2023 primarily reflects the payment of dividends, ~~the repayment of debt~~share repurchases and capital expenditures, ~~was~~ partially offset by the cash generated from operations in the first three months of ~~2022.~~2023. Working capital ~~declined from $11.1~~was $9.8 billion at March 31, 2023 and $9.7 billion at December 31, ~~2021 to $10.8 billion at March 31, 2022 as the~~2022. The increase in working capital in 2023 primarily reflects an increase in inventory and a decrease in accounts payable, partially offset by a decrease in cash and cash ~~equivalents and the increase in accounts payable were partially offset by increases in accounts receivable and inventory.~~

equivalents.

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first three months of ~~2022~~2023 totaled ~~$2.1~~approximately $1.1 billion, which reflects a decrease of ~~$572~~$922 million ~~compared to~~from the prior ~~year~~year. The decrease is primarily due to ~~an increased investment~~a decline in ~~various working capital components and~~operating earnings, partially offset by the timing of ~~pension and postretirement benefit plan contributions partially offset by higher operating earnings~~the collection of trade receivables and a reduction in cash taxes paid. ~~Cash~~In the first three months of 2023, Net cash from operating activities includes $282 million of pension contributions and the payment of cash taxes ~~paid in~~of approximately $122 million. In the first three months of 2022, ~~totaled approximately $195 million versus $270 million in 2021. Other, net in~~ Net cash from operating activities ~~was a use~~includes $334 million of ~~$205 million for~~pension contributions and the ~~first three months~~payment of ~~2022 and a use~~cash taxes of ~~$6 million for the first three months of 2021. The year-over-year change in Other, net in Net cash from operating activities primarily reflects the timing of benefit plan contributions.~~

approximately $195 million.

On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes ~~due 2022~~ upon maturity.

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes.As of March 31, ~~2022,~~2023, $2.15 billion of the $5 billion authorization remains available.

At March 31, ~~2022,~~2023, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and A1 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5$5.0 billion which expire in 2025.

~~Table of Contents~~

In December 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott’s common shares from time to time. The new authorization was in addition to the $1.081 billion portion of the share repurchase program authorized in 2019 that was unused as of December 31, 2021. In the first quarter of ~~2022,~~2023, Abbott repurchased ~~17.3~~approximately 3 million of its common shares for ~~$2.1 billion which fully utilized the authorization remaining under the 2019 share repurchase program and a portion of the 2021 authorization.~~ $300 million. As of March 31, ~~2022, $3.981~~2023, $2.134 billion remains available for repurchase under the ~~2021~~share repurchase ~~program.~~

program authorized by the board of directors in December 2021.

In the first quarter of ~~2022,~~2023, Abbott declared a quarterly dividend of ~~$0.47~~$0.51 per share on its common shares, which represents an increase of ~~4.4~~8.5 percent over the ~~$0.45~~$0.47 per share dividend declared in the first quarter of ~~2021.~~

2022.

Business Acquisition

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the ~~2021~~2022 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect ~~Abbott’s~~Abbott's operations are discussed in Item 1A, ~~“Risk Factors”~~"Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 4.Controls and Procedures

~~(a)~~

~~Evaluation of disclosure controls and procedures.~~ The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(a)

~~(b)~~

~~Changes in internal control over financial reporting.~~ During the quarter ended March 31, 2022, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

Evaluation of disclosure controls and procedures.

The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)Changes in internal control over financial reporting. During the quarter ended March 31, 2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, asincluding those described in our Annual Report on Form 10-K for the year ended December 31, 2021, including (as of March 31, 2022, except where noted below) those described below. While it is not feasible to predict the outcome of such pending claims, proceedings and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

In its 2021 Annual Report on Form 10-K, Abbott reported that it is a defendant in numerous lawsuits in federal and state courts involving certain of its specialty infant formula products administered to preterm infants. In April 2022, the U.S. Judicial Panel on Multidistrict Litigation ordered the consolidation of the federal court cases in the Northern District of Illinois for pretrial purposes.

2022.

~~Table of Contents~~

Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities


Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
January 1, 2023 - January 31, 2023	—	(1)	$	—	—	$	2,434,092,348	(2)
February 1, 2023 - February 28, 2023	600,000	(1)	100.933		600,000	2,373,532,278		(2)
March 1, 2023 - March 31, 2023	2,369,830	(1)	101.037		2,369,830	2,134,092,391		(2)
Total	2,969,830	(1)	101.016		2,969,830	$	2,134,092,391	(2)

~~(c)~~

~~Issuer Purchases of Equity Securities~~

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

(d) Maximum

Number (or

(c) Total Number

Approximate

of Shares (or

Dollar Value) of

(a) Total

Units) Purchased

Shares (or Units)

Number of

(b) Average

as Part of

that May Yet Be

Shares (or

Price Paid per

Publicly

Purchased Under

Units)

Share (or

Announced Plans

the Plans or

Period

Purchased

Unit)

or Programs

Programs

January 1, 2022 – January 31, 2022

650,000
⁽¹⁾
$
127.262

650,000

$
5,998,449,112
⁽²⁾
February 1, 2022 – February 28, 2022

8,550,000
⁽¹⁾

123.643

8,550,000

4,941,301,237
⁽²⁾
March 1, 2022 – March 31, 2022

8,113,060
⁽¹⁾

118.344

8,113,060

3,981,169,070
⁽²⁾
Total

17,313,060
⁽¹⁾
$
121.296

17,313,060

$
3,981,169,070
⁽²⁾

2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.

1.	~~These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.~~

On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time (the “2021 Plan”). The amount available for repurchase under the remaining portion of the 2019 Plan has been fully utilized as part of the share repurchases in the first quarter of 2022.

Table of Contents

Item 6.Exhibits


Exhibit No.						Exhibit

3.1						By-Laws of Abbott Laboratories, as amended and restated, effective April ~~29, 2022,~~28, 2023, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on February ~~22, 2022.~~17, 2023.

~~31.1~~ 10.1						Abbott Laboratories Non-Employee Directors' Fee Plan, as amended and restated.

31.1						Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2						Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1						Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2						Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101						The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, ~~2022,~~2023, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.

104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

~~ABBOTT LABORATORIES~~
ABBOTT LABORATORIES
~~By:~~
By:		/s/ ROBERT E. FUNCK, JR.
		Robert E. Funck, Jr.
		~~Robert E. Funck, Jr.~~
	Executive Vice President, Finance and Chief Financial Officer

		Date: May ~~3, 2022~~ 4, 2023


Part I - Financial Information
			Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings			3
Condensed Consolidated Statement of Comprehensive Income			4
Condensed Consolidated Balance Sheet			5
Condensed Consolidated Statement of Shareholders’ Investment			6
Condensed Consolidated Statement of Cash Flows			7
Notes to the Condensed Consolidated Financial Statements			8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			1920

Item 4. Controls and Procedures			2425

Part II - Other Information			25

Item 1. Legal Proceedings			2425

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			25

Item 6. Exhibits			26

Signature			27


	Three Months Ended
	March 31
	2022		2021
Net sales	$	11,895	$	10,456

Cost of products sold, excluding amortization of intangible assets		4,987		4,401
Amortization of intangible assets		512		509
Research and development		697		654
Selling, general and administrative		2,787		2,783
Total operating cost and expenses		8,983		8,347

Operating earnings		2,912		2,109

Interest expense		131		135
Interest (income)		(14)		(11)
Net foreign exchange (gain) loss		(3)		3
Other (income) expense, net		(78)		(61)
Earnings before taxes		2,876		2,043
Taxes on earnings		429		250
Net Earnings	$	2,447	$	1,793

Basic Earnings Per Common Share	$	1.38	$	1.00

Diluted Earnings Per Common Share	$	1.37	$	1.00

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share		1,761,911		1,776,842
Dilutive Common Stock Options		12,631		14,661
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options		1,774,542		1,791,503

Outstanding Common Stock Options Having No Dilutive Effect		2,655		2,694


	March 31,		December 31,
	2022		2021
Assets
Current Assets:
Cash and cash equivalents	$	7,675	$	9,799
Short-term investments		483		450
Trade receivables, less allowances of $640 in 2022 and $519 in 2021		7,179		6,487
Inventories:
Finished products		3,470		3,081
Work in process		695		694
Materials		1,526		1,382
Total inventories		5,691		5,157
Prepaid expenses and other receivables		2,401		2,346
Total Current Assets		23,429		24,239
Investments		763		816
Property and equipment, at cost		19,521		19,364
Less: accumulated depreciation and amortization		10,613		10,405
Net property and equipment		8,908		8,959
Intangible assets, net of amortization		12,225		12,739
Goodwill		23,179		23,231
Deferred income taxes and other assets		5,503		5,212
	$	74,007	$	75,196


	Three Months Ended March 31
	2022		2021
Common Shares:
Balance at January 1
Shares: 2022: 1,985,273,421; 2021: 1,981,156,896	$	24,470	$	24,145
Issued under incentive stock programs
Shares: 2022: 251,632; 2021: 1,048,595		14		47
Share-based compensation		324		304
Issuance of restricted stock awards		(504)		(473)
Balance at March 31
Shares: 2022: 1,985,525,053; 2021: 1,982,205,491	$	24,304	$	24,023

Common Shares Held in Treasury:
Balance at January 1
Shares: 2022: 221,191,228; 2021: 209,926,622	$	(11,822)	$	(10,042)
Issued under incentive stock programs
Shares: 2022: 4,144,476; 2021: 4,818,787		223		231
Purchased
Shares: 2022: 17,536,012; 2021: 277,508		(2,127)		(34)
Balance at March 31
Shares: 2022: 234,582,764; 2021: 205,385,343	$	(13,726)	$	(9,845)

Earnings Employed in the Business:
Balance at January 1	$	31,528	$	27,627
Net earnings		2,447		1,793
Cash dividends declared on common shares (per share — 2022: $0.47; 2021: $0.45)		(826)		(803)
Effect of common and treasury share transactions		146		52
Balance at March 31	$	33,295	$	28,669

Accumulated Other Comprehensive Income (Loss):
Balance at January 1	$	(8,374)	$	(8,946)
Other comprehensive income (loss)		(100)		(339)
Balance at March 31	$	(8,474)	$	(9,285)

Noncontrolling Interests in Subsidiaries:
Balance at January 1	$	222	$	219
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases		8		7
Balance at March 31	$	230	$	226


	Three Months Ended March 31, 2022						Three Months Ended March 31, 2021
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	902	$	902	$	—	$	821	$	821
Other		—		245		245		—		249		249
Total		—		1,147		1,147		—		1,070		1,070
Nutritionals —
Pediatric Nutritionals		338		509		847		508		558		1,066
Adult Nutritionals		339		708		1,047		328		642		970
Total		677		1,217		1,894		836		1,200		2,036
Diagnostics —
Core Laboratory		268		916		1,184		271		911		1,182
Molecular		172		248		420		175		272		447
Point of Care		91		37		128		92		37		129
Rapid Diagnostics		2,210		1,344		3,554		1,103		1,153		2,256
Total		2,741		2,545		5,286		1,641		2,373		4,014
Medical Devices —
Rhythm Management		248		276		524		241		278		519
Electrophysiology		216		269		485		179		252		431
Heart Failure		167		54		221		145		49		194
Vascular		209		410		619		219		416		635
Structural Heart		190		221		411		169		208		377
Neuromodulation		143		36		179		145		39		184
Diabetes Care		343		783		1,126		253		727		980
Total		1,516		2,049		3,565		1,351		1,969		3,320

Other		3		—		3		10		6		16

Total	$	4,937	$	6,958	$	11,895	$	3,838	$	6,618	$	10,456


(in millions)
Contract Liabilities:
Balance at December 31, 2021	$	520
Unearned revenue from cash received during the period		171
Revenue recognized related to contract liability balance		(178)
Balance at March 31, 2022	$	513


	Three Months Ended March 31
									Cumulative Gains (Losses)
	Cumulative Foreign				Net Actuarial (Losses) and				on Derivative Instruments
	Currency Translation				Prior Service (Costs) and				Designated as Cash Flow
	Adjustments				Credits				Hedges
(in millions)	2022		2021		2022		2021		2022		2021
Balance at January 1	$	(5,839)	$	(4,859)	$	(2,670)	$	(3,871)	$	135	$	(216)
Other comprehensive income (loss) before reclassifications		(106)		(536)		17		22		(34)		96
Amounts reclassified from accumulated other comprehensive income		—		—		45		63		(22)		16
Net current period comprehensive income (loss)		(106)		(536)		62		85		(56)		112
Balance at March 31	$	(5,945)	$	(5,395)	$	(2,608)	$	(3,786)	$	79	$	(104)


	Inventory-
	Related		Fixed Asset		Other Exit
(in millions)	Charges		Write-Downs		Costs		Total
Restructuring charges recorded in 2021	$	248	$	80	$	113	$	441
Payments		—		—		(90)		(90)
Other non-cash		(248)		(80)		—		(328)
Accrued balance at December 31, 2021		—		—		23		23
Payments and other adjustments		—		—		(3)		(3)
Accrued balance at March 31, 2022	$	—	$	—	$	20	$	20


(in millions)
Restructuring charges	$	68
Payments and other adjustments		(7)
Accrued balance at December 31, 2021		61
Payments and other adjustments		(16)
Accrued balance at March 31, 2022	$	45


	Outstanding		Exercisable
Number of shares		29,479,237		23,547,781
Weighted average remaining life (years)		5.9		5.1
Weighted average exercise price	$	69.87	$	59.23
Aggregate intrinsic value (in millions)	$	1,445	$	1,397


	Fair Value - Assets					Fair��Value - Liabilities
	March 31,		Dec. 31,			March 31,		Dec. 31,
(in millions)	2022		2021		Balance Sheet Caption	2022		2021		Balance Sheet Caption
Interest rate swaps designated as fair value hedges	$	—	$	87	Deferred income taxes and other assets	$	34	$	—	Post-employment obligations, deferred income taxes and other long-term liabilities
Foreign currency forward exchange contracts:
Hedging instruments		204		222	Prepaid expenses and other receivables		183		65	Other accrued liabilities
Others not designated as hedges		149		70	Prepaid expenses and other receivables		93		32	Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary		—		—	n/a		491		521	Long-term debt
	$	353	$	379		$	801	$	618


	Gain (loss) Recognized in				Income (expense) and
	Other Comprehensive				Gain (loss) Reclassified
	Income (loss)				into Income
(in millions)	2022		2021		2022		2021		Income Statement Caption
Foreign currency forward exchange contracts designated as cash flow hedges	$	(49)	$	134	$	27	$	(23)	Cost of products sold
Debt designated as a hedge of net investment in a foreign subsidiary		30		35		—		—	n/a
Interest rate swaps designated as fair value hedges		n/a		n/a		(121)		(69)	Interest expense


	March 31, 2022				December 31, 2021
	Carrying		Fair		Carrying		Fair
(in millions)	Value		Value		Value		Value
Long-term Investment Securities:
Equity securities	$	703	$	703	$	748	$	748
Other		60		60		68		68
Total long-term debt		(17,090)		(18,704)		(18,050)		(21,152)
Foreign Currency Forward Exchange Contracts:
Receivable position		353		353		292		292
(Payable) position		(276)		(276)		(97)		(97)
Interest Rate Hedge Contracts:
Receivable position		—		—		87		87
(Payable) position		(34)		(34)		—		—


			Basis of Fair Value Measurement
			Quoted		Significant
			Prices in		Other		Significant
	Outstanding		Active		Observable		Unobservable
(in millions)	Balances		Markets		Inputs		Inputs
March 31, 2022:
Equity securities	$	367	$	367	$	—	$	—
Foreign currency forward exchange contracts		353		—		353		—
Total Assets	$	720	$	367	$	353	$	—

Fair value of hedged long-term debt	$	2,805	$	—	$	2,805	$	—
Interest rate swap derivative financial instruments		34		—		34		—
Foreign currency forward exchange contracts		276		—		276		—
Contingent consideration related to business combinations		134		—		—		134
Total Liabilities	$	3,249	$	—	$	3,115	$	134

December 31, 2021:
Equity securities	$	402	$	402	$	—	$	—
Interest rate swap derivative financial instruments		87		—		87		—
Foreign currency forward exchange contracts		292		—		292		—
Total Assets	$	781	$	402	$	379	$	—

Fair value of hedged long-term debt	$	2,926	$	—	$	2,926	$	—
Foreign currency forward exchange contracts		97		—		97		—
Contingent consideration related to business combinations		130		—		—		130
Total Liabilities	$	3,153	$	—	$	3,023	$	130


	Defined Benefit Plans				Medical and Dental Plans
	March 31,		March 31,		March 31,		March 31,
(in millions)	2022		2021		2022		2021

Service cost — benefits earned during the period	$	96	$	100	$	13	$	14
Interest cost on projected benefit obligations		76		62		10		8
Expected return on plan assets		(236)		(211)		(7)		(7)
Net amortization of:
Actuarial loss, net		59		81		5		7
Prior service cost (credit)		—		—		(6)		(7)
Net cost (credit)	$	(5)	$	32	$	15	$	15


	Three Months Ended March 31
	Net Sales to				Operating
	External Customers				Earnings
(in millions)	2022		2021		2022		2021
Established Pharmaceutical Products	$	1,147	$	1,070	$	242	$	169
Nutritional Products		1,894		2,036		251		467
Diagnostic Products		5,286		4,014		2,569		1,701
Medical Devices		3,565		3,320		1,078		1,007
Total Reportable Segments		11,892		10,440		4,140		3,344
Other		3		16
Net sales	$	11,895	$	10,456
Corporate functions and benefit plans costs						(114)		(114)
Net interest expense						(117)		(124)
Share-based compensation (a)						(305)		(288)
Amortization of intangible assets						(512)		(509)
Other, net (b)						(216)		(266)
Earnings before taxes					$	2,876	$	2,043


	Net Sales to External Customers
	Three Months		Three Months
	Ended		Ended				Impact of		Total Change
	March 31,		March 31,		Total		Foreign		Excl. Foreign
(in millions)	2022		2021		Change		Exchange		Exchange

Established Pharmaceutical Products	$	1,147	$	1,070	7.1	%	(6.3)	%	13.4	%
Nutritional Products		1,894		2,036	(7.0)		(2.6)		(4.4)
Diagnostic Products		5,286		4,014	31.7		(3.4)		35.1
Medical Devices		3,565		3,320	7.4		(4.1)		11.5
Total Reportable Segments		11,892		10,440	13.9		(3.8)		17.7
Other		3		16	(85.8)		—		(85.8)
Net Sales	$	11,895	$	10,456	13.8		(3.7)		17.5

Total U.S.	$	4,937	$	3,838	28.6		—		28.6

Total International	$	6,958	$	6,618	5.1		(6.0)		11.1


						(d) Maximum
						Number (or
					(c) Total Number	Approximate
					of Shares (or	Dollar Value) of
	(a) Total				Units) Purchased	Shares (or Units)
	Number of		(b) Average		as Part of	that May Yet Be
	Shares (or		Price Paid per		Publicly	Purchased Under
	Units)		Share (or		Announced Plans	the Plans or
Period	Purchased		Unit)		or Programs	Programs
January 1, 2022 – January 31, 2022	650,000	⁽¹⁾	$	127.262	650,000	$	5,998,449,112	⁽²⁾
February 1, 2022 – February 28, 2022	8,550,000	⁽¹⁾		123.643	8,550,000		4,941,301,237	⁽²⁾
March 1, 2022 – March 31, 2022	8,113,060	⁽¹⁾		118.344	8,113,060		3,981,169,070	⁽²⁾
Total	17,313,060	⁽¹⁾	$	121.296	17,313,060	$	3,981,169,070	⁽²⁾

Large Accelerated Filer ☒x

Accelerated Filer ☐o

Non-Accelerated Filer ☐o

Smaller reporting company ☐o

Emerging growth company ☐o